Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

NASDAQ:AEZS opened at $2.90 on Tuesday. The stock’s 50-day moving average is $3.41 and its 200-day moving average is $4.77. Aeterna Zentaris has a 1-year low of $3.96 and a 1-year high of $12.00. The stock has a market cap of $5.20 million, a P/E ratio of -0.20 and a beta of 1.55.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.